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Abstract
Introduction: A CD4 count <200 at diagnosis results in negative health outcomes and suggests 
delays in HIV testing. 
Objectives: To describe the timeliness of HIV diagnosis in Newfoundland and Labrador (NL) 
and explore the reasons for delay. 
Methods: Demographic and clinical information from new HIV diagnoses in NL between 2006-
2016 were collected (n=58). Subjects were invited to interviews regarding testing barriers.  
Results: At diagnosis the mean age was 40.6, 53/58 (91.4%) were male, 33/58 (56.9%) were 
men who have sex with men, and 21/58 (36.2%) had a CD4 count <200. For 39/58 (67.2%), their 
first test was positive, though 55/58 (94.8%) had previous healthcare contact. Heterosexuals 
were more likely to present late (p=0.049). Barriers to testing were negative healthcare 
interactions, stigma, being unaware of their risk, and fear of the diagnosis. 
Conclusions: We defined missed opportunities for testing. Heterosexual men are more likely to 
test late. Late diagnosis may be prevented if testing is normalized.
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11.0 – Introduction
1.1 – The Problem with a Late HIV Diagnosis
According to the Public Health Agency of Canada, as of 2014 there are 75,500 people 
living in Canada that are HIV-positive. Of these, it is estimated that 21% are not aware of their 
HIV status [1]. HIV results in the destruction of CD4+ T lymphocytes which are crucial to the 
normal function of the human immune system. A CD4 count is used to measure how many of 
these lymphocyte cells are remaining and thus indicate impaired immune function [2]. Early 
diagnosis and entry into care are essential for positive outcomes. A late diagnosis is associated 
with a lower CD4 count and thus a higher rate of opportunistic infections, lower quality of life 
[3] and higher mortality rate [3][4]. In particular, a low CD4 count is associated with a higher 
mortality due to AIDS, infection, non-AIDS malignancy and renal failure among other causes of 
death [5]. The Association of Medical Microbiology and Infectious Diseases Canada 
recommends initiating antiretroviral treatment at HIV diagnosis, regardless of CD4 count [6]. 
Treatment should be started as soon as an individual reaches a CD4 count <350 cells/mm3, if 
possible, to avoid the previously mentioned negative outcomes [7]. Initiating antiretroviral 
treatment with a low CD4 count also carries an increased risk of treatment failure [8]. 
Furthermore, a late diagnosis increases the risk of HIV being transmitted unknowingly. It is 
estimated that an early diagnosis decreases the lifetime transmission rate by almost 50% [3]. In a 
meta-analysis by Marks et al., it was shown that unprotected anal or vaginal sex decreased by 
68% in persons aware they were HIV-positive compared to those who were not aware they were 
HIV-positive, when their partners were HIV-negative [9], meaning that awareness of HIV 
diagnosis may change risk factors for transmission. A late diagnosis also has a high economic 
2impact. In Alberta, it was determined that people presenting with CD4 counts of <350 cells/mm3 
had significantly higher costs during the first year of accessing care and medical costs remained 
almost twice as high in subsequent years [10].  
1.2 – Normalizing Testing
In the Public Health Agency of Canada’s (PHAC) guidelines for HIV testing, it states “It is 
recommended that the consideration and discussion of HIV testing be made a component of 
periodic routine medical care. This recommendation is based upon the current body of good 
quality evidence demonstrating the individual and public health benefits associated with 
normalising HIV testing”[11]. The PHAC guidelines also state that testing should be discussed 
by all care providers involved in HIV testing including primary care providers, nurses, 
counsellors, social workers, community health workers, midwives and community-based service 
providers. PHAC lists those who they recommend should be offered HIV testing which includes 
anyone sexually active who has never been tested before, anyone who had unprotected sex, and 
anyone asking for a test, among many other individuals [11]. It is recommended that individuals 
involved in high risk practices should be screened for HIV at least annually, while frequency for 
all populations should be decided on by the health care provider based on the individual’s sexual 
history, the prevalence of HIV in the individual’s demographic group and the prevalence of HIV 
in the geographical area [11]. Normalising HIV testing and making it a part of routine testing 
will reduce the prevalence of late diagnosis (LD) of HIV. In Canada, opt-out testing (testing 
which is included automatically as a routine test in which the individual has the right to refuse) is 
confined to prenatal screening and only in some provinces [12]. Opt-out testing has been shown 
to increase testing uptake. In Scotland, for example, routine opt-out HIV testing in genitourinary 
3medicine clinics was introduced in 2005 whereby all patients were offered an HIV test. This 
resulted in a significant (p<0.001) increase in HIV testing [13]. Furthermore, in an HIV testing 
campaign in London called “TestMeEast”, HIV testing was offered to individuals having a 
routine blood test with 2402 (55.6%) of individuals getting tested [14]. This resulted in three new 
HIV diagnoses. The campaign used the hashtag #TestMeEast on twitter which reached 238,860 
people [14]. In a 2014/2015 Australian point of care HIV campaign called “RAPID”, 1,199 
people received a free HIV test, 17.1% of which were first-time testers [15]. All of these efforts 
may have helped to normalize HIV testing and resulted in an increased uptake in HIV testing.
1.3 – Definition of Late HIV Diagnosis
The definition of a late HIV diagnosis has changed over time and still there is no 
consensus worldwide [4][10]. In Europe, a late presentation was defined as a CD4 count <350 
cells/mm3  or an AIDS-defining event, and advanced HIV was defined as a CD4 count <200 
cells/mm3  or an AIDS-defining event [16]. AIDS-defining events are illnesses listed by the 
Center for Disease Control (CDC) that are associated with severely immunocompromised 
individuals (Eg. Cytomegalovirus, Kaposi sarcoma, Lymphoma, Pneumocystis jirovecii 
pneumonia, etc.) [17].  Another study in China elaborated on this definition to include that the 
individuals must have met the <350 cells/mm3 or <200 cells/mm3 criteria within one month of 
HIV diagnosis, which would include those who are delayed in acquiring CD4 testing after HIV 
diagnosis [4]. Even with these two consensus definitions being suggested, many articles still use 
terms like “late diagnosis”, “delayed diagnosis” and “late presentation” interchangeably, with 
various CD4 criteria. 
41.4 – Late Diagnosis Prevalence
It is difficult to compare the prevalence of late HIV diagnosis in other provinces due to 
variations in definition, years, and data available. Table 1.1 summarizes information regarding 
late diagnosis of HIV in five previous surveillance reports. From these reports, the prevalence of 
late HIV diagnosis ranged from 8.8% in five provinces to 30% in Manitoba[18]–[22]. 
Table 1.1: The Prevalence of late diagnosi of HIV in Other Canadian Provinces
Definition of LD Year Prevalence of LD
British Columbia [18] AIDS diagnosis 
before or up to 12 
months after the date 
of the first positive 
HIV test, or CD4 
count ˂200 cells/mm3
2010-2014 26.6%
Manitoba [19] <200 cells/mm3 when 
entering care
2015 30%
Nova Scotia [22] Initial CD4 count of 
<200 cells/mm3 
within 6 months of 
HIV diagnosis
2001-2010 24.7%
Ontario [20] CD4 count <200 
cells/mm3 at 
diagnosis
1997-2009 29%
Nationwide* [21] CD4 count of <200 
cells/mm3 or presence 
of an opportunistic 
illness within 3 
months of diagnosis.
2010 8.8%
* Data from five provinces in which AIDS cases were reported systematically and consistently. May not 
be nationally representative.
51.5 – Demographic Factors as a Predictor for Late Diagnosis
Demographic factors have also been suggested to predict whether an individual that is 
HIV-positive will present with an early or late diagnosis. In Nova Scotia, older age was the only 
demographic factor that significantly predicted a late diagnosis [22]. In British Columbia, 
heterosexual individuals were more likely to have a late diagnosis compared to men who have 
sex with men (MSM) [18]. 
In a study involving 34 European countries from 2010-2013, late presentation (defined as 
a CD4 count of <350 cells/mm3 or an AIDS-defining event) occurred in 62.4% of heterosexual 
men, 52.2% of heterosexual women and 39.0% of MSM, suggesting heterosexual men may be 
less likely to get tested for HIV than MSM. The median age of individuals that were late 
presenters was 39 years (IQR=31-48) compared to 36 years (IQR=29-45) for all HIV diagnoses.  
[23]. 
In a comprehensive inter-country comparison, Hall et al. described patient demographics  
associated with a late diagnosis from surveillance reports in Australia, Canada, France, Italy and 
the United States in 2009 and 2010 [21]. A late diagnosis was defined as an AIDS diagnosis 
within 3 months of HIV diagnosis. Table 1.2 summarizes the prevalence of a late diagnosis in 
various demographic groups. In the majority of countries, older age, heterosexuality and IVDU 
were all predictors of a late HIV diagnosis. Canada has the lowest prevalence of late diagnosis, 
and the United States has the highest prevalence of late diagnosis.
6Table 1.2: The prevalence of late diagnosis in various demographic groups in five countries
Age Sex Transmission 
Category
Australia 0-9: 0.0%
10-19: 6.3%
20-29: 9.0%
30-39: 17.1%
40-49: 24.1%
50+: 32.3%
Male: 18.4%
Female: 21.3%
Transgender: 20.0%
MSM: 13.3%
IVDU: 26.1%
MSM-IVDU: 27.3%
Heterosexual: 29.5%
Canada 0-9: 0.0%
10-19: 0.0%
20-29: 2.6%
30-39: 6.8%
40-49: 13.8%
50+: 13.7%
Male: 9.5%
Female: 5.9%
Transgender: No data
MSM: 7.4%
IVDU: 8.7%
MSM-IVDU: 7.7%
Heterosexual: 8.7%
France 0-9: 17.1%
10-19: 6.8%
20-29: 7.6%
30-39: 13.1%
40-49: 18.4%
50+: 26.3%
Male: 16.5%
Female: 12.8%
Transgender: No data
MSM: 11.8%
IVDU: 27.0%
MSM-IVDU: --
Heterosexual: 17.4%
Italy 0-9: 0.0%
10-19: 2.9%
20-29: 6.9%
30-39: 11.5%
40-49: 17.5%
50+: 25.9%
Male: 14.3%
Female: 15.3%
Transgender: 0.0%
MSM: 11.5%
IVDU: 16.1%
MSM-IVDU: --
Heterosexual: 18.1%
United States 0-9: 7.3%
10-19: 12.8%
20-29: 16.8%
30-39: 29.9%
40-49: 37.3%
50+: 42.1%
Male: 29.1%
Female: 27.4%
Transgender: No data
MSM: 26.7%
IVDU: 39.1%
MSM-IVDU: 28.0%
Heterosexual: 30.4%
71.6 – Missed Opportunities to Test for HIV
Numerous studies worldwide suggest that health care workers miss opportunities to test 
for HIV, thus resulting in a later diagnosis. In a British study involving 1,112 HIV-positive 
patients, 25.2% were found to have visited a health care provider (HCP) with an HIV-indicator 
condition, but had not been tested [24]. In another study in Spain, 99,426 patients were 
diagnosed with a total of 102,647 HIV-indicator conditions, of which only 18.5% of cases were 
tested for HIV within 4 months [25]. In Denmark, out of a cohort of 1,051 HIV-positive 
individuals diagnosed with a CD4 count <200 cells/mm3, 40.0% had attended a hospital 1-3 
years prior to diagnosis [26]. In New York, in a cohort of 253 patients diagnosed with HIV, 
60.1% had accessed the health care system within 3 years prior to diagnosis indicating potential 
missed opportunities for an earlier diagnosis [27]. Major reasons for missed opportunities by 
healthcare workers included fear of making their patient feel uncomfortable [28]–[32], time and 
financial constraints [21][22][24][25] and inadequate HIV training and education [30]–[33].
1.7 – Barriers to HIV Testing
There are also numerous barriers to HIV testing that have been observed in previous 
Canadian studies. In a nationwide study involving young Aboriginals, the main reasons for not 
getting tested for HIV were the perception of not being at risk, perception that they had not been 
exposed to HIV, not experiencing any symptoms, their HCP not recommending testing, and not 
wanting to know their HIV status [34]. In a study on transgender people in Ontario, the main 
reasons to not get tested for HIV were the fear of a positive result, difficulty accessing 
8healthcare, their HCP believing they are low risk and having low knowledge about HIV, and 
various issues relating to being transgender [35]. 
In a study in Ottawa, attitudes towards HIV regarding HIV-serostatus disclosure, 
nondisclosure prosecutions and public health were examined in the MSM population.  Both HIV-
positive and HIV-negative individuals were interviewed. The men reported a stigma associated 
with being HIV-positive and concern about the legality and confidentiality of disclosure of HIV 
status [36]. These may also be barriers that would prevent MSM from getting tested for HIV. A 
British Columbia study involving MSM found that 35% of individuals had not told their HCP 
that they were homosexual and thus they may have been perceived as being lower risk for HIV 
and therefore not offered a test [37]. 
In a comprehensive review of studies involving barriers to HIV testing in Canada, the 
United Kingdom and Australia from 2003-2013, barriers were described at the intrapersonal 
level, interpersonal level, and extra-personal level [38]. Barriers in the intrapersonal level 
included fear of a positive diagnosis, internalized stigma about HIV, low perception of risk, low 
awareness of public services and poor knowledge of HIV. At the interpersonal level, barriers 
included not being offered a test by a HCP, negative experiences with HCPs, stigma of testing 
and HIV, fear of confidentiality breaches, fear of a HIV diagnosis affecting employment and 
insurance, and nondisclosure of sexual orientation to a HCP thus being perceived at low risk. At 
the extra-personal level, barriers to testing included policies surrounding HIV testing, 
accessibility of testing, the need to return for results, and laws surrounding sex workers and 
intravenous drug users discouraging them from getting tested [38]. The barriers that were 
mentioned in at least two of these studies were the perception of not being at risk for contracting 
9HIV, a HCP not recommending testing, fear of a positive HIV diagnosis and the stigma 
associated with HIV.
1.8 - HIV Testing in Newfoundland and Labrador
In NL HIV testing is offered nominally (the test includes the individuals name), non-nominally 
(the HCP knows the patient but the test is ordered using a code or the initials of the person being 
tested) and anonymously (the HCP does not know the name of the individual) [39]. However, if 
an individual tests positive for HIV through anonymous testing, follow-up care and HIV data 
reporting are all done nominally. While anonymous testing is available upon request, it is not 
part of the official guidelines for the province [39]. HIV testing in NL requires a blood test but 
there is an ongoing study currently offering point of care finger prick HIV screening in two 
locations in the province until July 2017 [40].
1.9 – Study Objectives
The main objectives of this study were:
1. To investigate the prevalence of delayed HIV diagnosis in Newfoundland and Labrador
2. To determine demographic factors associated with a delayed diagnosis
3. To determine if there are missed opportunities for diagnosis
4. To examine potential barriers to HIV testing
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The secondary objective of this study was:
1. To determine how provincial/national HIV testing policy might be modified to reduce late 
diagnosis. 
While previous research has been done on these study objectives, there is little research in 
Canada and none in Newfoundland and Labrador. 
The role of Sarah Boyd was data collection, analysis, and primary author of this thesis.
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2.0 - Methods
This study was conducted in two parts. In part 1, a quantitative study was performed 
using a retrospective chart review. In part 2, a qualitative study was conducted using semi-
structured interviews with persons living with HIV. 
2.1 – Ethics Statement
Ethics approval was given by the Health Research Ethics Board (HREB) of 
Newfoundland and Labrador for both parts of the study (Approved 18/08/2016, reference HREB 
2016.181). The Research Proposals Approval Committee of Eastern Health also approved the 
study. 
Informed Consent was not obtained for the retrospective chart review, but was obtained 
prior to conducting interviews. For the qualitative study, a nurse from the St. John’s HIV clinic 
contacted potential participants and if they agreed to an interview, the names and phone numbers 
were then given to the research team. The voice recordings of the interviews were deleted after 
transcription and the transcribed interviews were stored on a password protected, encrypted hard 
drive. Consent forms, case report forms, and all other study material were stored in a locked file 
in Dr. Peter Daley’s office. Names were removed from transcripts and a numerical code was 
created and stored in a different file to ensure confidentiality. 
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2.2 - Quantitative Study
2.2.1 – Study Design 
The quantitative portion of the current study involved a retrospective chart review of 
individuals aged 18 years and older that were diagnosed with HIV in Newfoundland and 
Labrador (NL) between January 2006 and June 2016. A list of all individuals diagnosed HIV-
positive in NL in this timeframe was received from the HIV Clinic in St. John’s. Even if an 
individual had never been to the clinic, their name was still included on this list as the names of 
all individuals diagnosed with HIV in NL are sent to the clinic by the CDC. Individuals were 
then screened for eligibility. Patient information was acquired from paper charts and an 
electronic medical file by a research student. When individuals were first seen at the HIV clinic, 
the nurse would ask many questions regarding their risk factors and symptoms which would be 
uploaded to their electronic medical file. This was the main source of data for this study. If this 
history could not be found in the electronic file, other sections of the file were searched for 
relevant information, paper charts were searched and any remaining questions were asked to the 
nurse in person. Most of the information was readily available through the electronic charts.  
2.2.2 – Main Outcome
The main outcome for the quantitative portion of the study was the CD4 count at 
diagnosis to determine if any demographic factors or other variables could predict late HIV 
diagnosis.
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2.2.3 – Variables Collected
Demographic information such as age at diagnosis, gender, residence and employment 
were collected as well as risk factor information such as sexual orientation, intravenous drug use, 
maternal to child transmission, intravenous drug use, and whether an individual originated from 
an HIV-endemic country. Furthermore, the following information regarding HIV testing was 
collected: number of previous HIV tests, the date of last HIV test, date of positive test, who 
initiated testing, where the test was performed and CD4 count at diagnosis. The following 
disease information was collected: other STIs, AIDS-indicator conditions and symptoms 
experienced at diagnosis. Information regarding previous healthcare contact was recorded 
including the number of clinic visits, emergency room (ER) visits and hospital admissions within 
five years prior to HIV diagnosis. The number of visits with a patient’s family doctor was 
unavailable. Finally, smoking status, alcohol use and drug use were recorded. 
2.2.4 – Data Analysis
All data was entered into SPSS Version 22 and a statistical analysis was performed. As 
the distribution of CD4 at diagnosis (see Figure 1) was not normal, nonparametric tests were 
used to compare the mean CD4 count of different variable categories to determine if certain 
demographics or characteristics were associated with a later diagnosis. A Mann-Whitney U test 
was used for variables with two categories and a Kruskal-Wallis test was used for variables with 
three or more categories. Mean CD4 count with standard deviation was also determined for each 
variable.
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2.3 – Qualitative Study
2.3.1 – Study Design
All individuals who met inclusion criteria for the quantitative study were invited to 
participate in semi-structured interviews regarding HIV testing. The nurse at the HIV clinic 
contacted each patient to determine if they were interested in participating in an interview. A list 
of individuals who were interested was given to the research assistant who then called the 
patients to further discuss the study and set-up interview times if they were still interested. All 
interviews took place between November 2016 and January 2017. Interviews were conducted via 
telephone or in person and informed consent was obtained prior to the commencement of 
interviews. Interviews were recorded, transcribed and coded for important issues and themes 
regarding HIV in NL. 
2.3.2 – Main Outcome
The main outcome for the qualitative portion of the study was factors influencing HIV 
testing. Secondary outcomes included all other information regarding HIV testing and living 
with HIV. 
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2.3.3 – Variables Collected
The questions were open-ended and invited a narrative response. Participants were asked 
the following questions specifically:  whether the individual thought they were at risk for 
acquiring HIV, if they knew the risk factors for HIV prior to their diagnosis, what led them to 
decide to get tested, whether they requested testing or if their doctor suggested it, information 
they were given about HIV before and after their positive diagnosis, barriers to HIV testing, how 
their life has changed since their diagnosis and other information regarding testing in their 
community. The interview guide can be found in appendix D.
2.3.4 - Data Analysis
Validity was ensured through inter-rater coder agreement, member checking and 
qualitative data software analysis.  Three different people on the research team independently 
read through the interview transcripts after names were removed and identified key themes from 
the data.  These themes were compared for consistency between the three researchers. The 
qualitative analysis software NVivo was also used to ensure no important themes were missed by 
scanning the text for keywords and sorting coded information for further thematic analysis. 
When final themes had been developed and agreed upon by the researchers, two individuals who 
participated in the interviews were shown their transcribed interview with themes and asked if 
they agreed with the researchers’ analysis.
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3.0 - Results
3.1 - Quantitative Study
A total of 66 individuals were diagnosed with HIV in NL between January 2006 and June 
2016. After reviewing their medical charts, it was found that 8 had been previously diagnosed 
HIV-positive outside the province and were therefore excluded from the study. Of the 58 people 
diagnosed with HIV, 21 (36.2%) were diagnosed with a CD4 count < 200 cells/mm3 and thus had 
a late diagnosis. Ten (17.2%) had a CD4 count of 30 cells/mm3 or less. Figure 1 shows a flow 
chart of the participants.
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Figure 3.1: Flow chart showing individuals included in the study with an early and late diagnosis
66 individuals 
screened for inclusion
Excluded:
8 individuals previously 
diagnosed HIV-positive 
outside of NL
58 HIV-positive individuals 
diagnosed in NL between 
January 2006 and June 2016
(n=58 for Quantitative Study)
21 diagnosed with 
CD4 count < 200
37 diagnosed with 
CD4 count > 200
10 agreed to an 
interview
(n=10 for Qualitative 
Study)
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Figure 3.2: Histogram Showing the CD4 Count at HIV Diagnosis
Figure 3.2 shows the distribution of CD4 counts at diagnosis. The highest category of 
CD4 count is 0-50 cells/mm3 with 11 individuals. The data is not normally distributed. 
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Table 3.1: Patient Demographics
Total Mean CD4 at 
Diagnosis 
P-value
Total 58 (100%) 387 ------------------
Sex:
       Male
       Female
53 (91.4%)
  5 (8.6%)
390
355
0.957a
Residence:
       Urban
       Rural
50 (86.2%)
  8 (13.8%)
364
533 
0.392a
Age: 
        20-29
        30-39
        40-49
        50+
12 (20.7%)
11 (19.0%)
24 (41.4%)
11 (19.0%)
495
324
388
329
0.812b
Employment:
      Unemployed
      Part-time
      Full-time
      Retired
      Disabled
      Student
13 (22.4%)
  5 (8.6%)
33 (56.9%)
  2 (3.4%)
  1 (1.7%)
  4 (6.9%)
366
289
392
258
396
602
0.881b
a = Mann-Whitney U Test
b =  Kruskal-Wallis Test
As seen in Table 3.1, most individuals diagnosed with HIV were middle-aged men living 
in urban NL that work full-time. There was no significant difference of CD4 count at diagnosis 
between sex, residence, age or employment. 
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Table 3.2: HIV Risk Factors
Total Mean CD4 at 
Diagnosis 
P-value
Sexual 
Orientation:
      MSM
      Heterosexual
      Unknown
33 (56.9%)
21 (36.2%)
  4 (6.9%)
449
262
----
0.049a
IVDU:
       Yes
       No
  2 (3.4%)
56 (96.6%)
387
387
0.818a
From HIV-
endemic country: 
        Yes
        No
        Unknown
  3 (5.2%)
49 (84.5%)
  6 (10.3%)
140
410
----
0.207a
Blood 
Transfusion:            
         Yes
         No
  1 (1.7%)
57 (98.3%)
174
391
0.690a
Maternal 
Transmission:            
         Yes
         No
  0 (0%)
58 (100%)
------------------- -------------------
a = Mann-Whitney U Test
Table 3.2 describes the risk factors of individuals diagnosed with HIV. The highest 
number of people were MSM, with very few IVDUs and people from HIV-endemic countries. 
There was only one patient that had had a blood transfusion, and no patients contracted HIV 
through maternal transmission. There was a significant difference of CD4 count between MSM 
and heterosexual individuals with MSM having a higher CD4 count. There was no significant 
differences for categories of IVDU, originating from an HIV-endemic country of blood 
transfusion though there are few individuals in these groups. Furthermore, MSM had 
significantly more HIV tests than heterosexual individuals (p=0.036).  
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Table 3.3: Testing history
Total Mean CD4 at 
Diagnosis 
P-value
Who Initiated 
Testing:
      HCP
      Patient
      Insurance     
      Immigration
      Unknown
35 (60.3%)
15 (25.9%)
  4 (6.9%)
  2 (3.4%)
  2 (3.4%)
369
457
378
124
----
0.292b
Site of Diagnosis:
      Hospital
      Primary Care
      ER
      STI Clinic
      HIV Clinic
10 (17.2%)
22 (37.9%)
  1 (1.7%)
19 (32.8%)
  6 (10.3%)
  89
358
    3
579
448
0.001b
(p=0.001 when 
comparing 
Hospital to STI 
Clinic)
Number of 
Previous HIV 
Tests:
       0
       1-2
       3+
  
39 (67.2%)
12 (20.7%)
  7 (12.1%)
308
604
456
0.021b
(p = 0.031 when 
comparing 0 to 
1-2 visits)
Tested Within a 
Year Before 
Diagnosis:
         Yes
         No
  
  9 (15.5%)
49 (84.5%)
683
333
0.004a
a = Mann-Whitney U Test
b =  Kruskal-Wallis Test
As seen in Table 3.3, HIV testing was initiated by healthcare workers most of the time, 
with the patient asking for the test approximately a quarter of the time. Four individuals were 
tested for HIV for insurance purposes. Regarding the site of diagnosis, most individuals were 
diagnosed in primary care or at a STI clinic. For 67.2% of patients, the first time they were tested 
for HIV was when they were diagnosed HIV-positive, and 84.5% had not been tested within a 
year prior to their diagnosis. There was no significant difference in CD4 count based on who 
22
initiated the HIV test. There was however, a significant difference in CD4 count based on where 
the individual was diagnosed (lower in the hospital and ER), the number of previous HIV tests, 
and whether the individual was tested for HIV a year before they were diagnosed.
Table 3.4: Previous Healthcare Contact 
Total Mean CD4 at 
Diagnosis 
P-value
Clinic Visits:
       0
       1-9
       10-19
       20+
8 (13.8%)
33 (56.9%)
9 (15.5%)
8 (13.8%)
469
383
330
387
0.910b
ER Visits:
       0
       1-4
       5-9
       10+
15 (25.9%)
28 (48.3%)
9 (15.5%)
6 (10.3%)
402
415
364
256
0.652b
Hospital 
Admissions: 
        0
        1
        2
        3
48 (82.8%)
8 (13.8%)
1 (1.7%)
1 (1.7%)
405
307
528
16
0.374b
b =  Kruskal-Wallis Test
Table 3.4 shows previous healthcare contact within 5 years prior to HIV diagnosis . 
86.2% of individuals had attended a clinic, 74.1% had been to the ER, and 17.2% had been 
admitted to hospital. Overall, 94.8% of individuals had at least one contact within the healthcare 
system. Clinic visits ranged from 0-61, ER visits ranged from 0-18, and hospital admissions 
ranged from 0-3. The mean number of all healthcare contact visits was 13.7. There was no 
significant difference between categories of clinic visits, ER visits and hospital admissions. For 
ER visits, it appears that there is a trend that the more visits, the lower the CD4 count at 
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diagnosis. Reasons for ER visits were recorded and many were issues regarding feeling generally 
unwell, fatigue and shortness of breath. However, it should be noted that there were visits that 
are irrelevant to HIV, for example, trauma. During these visits it is unlikely that an ER physician 
would consider HIV testing, however, if opt-out testing was put in place, HIV cases would not 
be missed.
Table 3.5: Substance Use
Total Mean CD4 at 
Diagnosis 
P-value
Smoker:
      Yes
      No
      Unknown
30 (51.7%)
24 (41.4%)
  4 (6.9%)
403
336
----
0.236a
Alcohol user:
      Yes
      No
      Unknown
34 (58.6%)
18 (31.0%)
  6 (10.3%)
417
263
----
0.053a
Illicit Drug user:
      Yes
      No
      Unknown
21 (36.2%)
32 (55.2%)
5 (8.6%)
445
350
----
0.429a
a = Mann-Whitney U Test
Table 3.5 shows that most of the individuals were smokers and alcohol users while over a 
third were drug users. Marijuana was the most common drug used. There was no statistically 
significant difference between CD4 count at diagnosis for the different categories of substance 
use.  Notably, patients who denied alcohol use trend to a later diagnosis.
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Table 3.6: Sexually Transmitted Infections Present at HIV Diagnosis
Syphilis:
       Yes 
       No 
       Test Not Done
  9 (15.5%)
38 (65.5%)
11 (19.0%)
Hepatitis C:
       Yes 
       No 
       Test Not Done
  3 (5.2%)
49 (84.5%)
  6 (10.3%)
Chlamydia
       Yes 
       No 
       Test Not Done
  3 (5.2%)
16 (27.6%)
39 (67.2%)
Gonorrhea:
       Yes 
       No 
       Test Not Done
 
  1 (1.7%)
18 (31.0%)
39 (67.2%)
Table 3.6 lists other sexually transmitted infections (STIs) that were concurrently 
diagnosed with HIV. The most common STI was syphilis which occurred in 15.5% of cases, 
followed by Hepatitis C and Chlamydia in 5.2% of cases and Gonorrhea in 1.7% of cases. Some 
individuals were not tested for STIs other than HIV, and over two-thirds of patients were not 
tested for Chlamydia or Gonorrhea. 
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Table 3.7: AIDS-Indicator Conditions Present at HIV diagnosis
Pneumocystis jiroveci Pneumonia 6 (10.3%)
Cytomegalovirus 4 (6.9%)
Lymphoma 2 (3.4%)
Table 3.7 lists AIDS-Indicator conditions (AIC) at the time of HIV diagnosis. Overall, 8 
(13.8%) individuals had one or more AIC with the most common being Pneumocystis 
Pneumonia (6 cases) followed by Cytomegalovirus (4 cases) and Lymphoma (2 cases). For the 4 
cases of Cytomegalovirus, 1 case was Cytomegalovirus retinitis and the other 3 cases were 
written only as “Cytomegalovirus” in the patient files, therefore the type is unknown. 
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Table 3.8: Symptoms at HIV Diagnosis
Asymptomatic 20 (34.5%)
Swollen Lymph Nodes 19 (32.8%)
Weight Loss 17 (29.3%)
Fatigue 16 (27.6%)
Thrush 13 (22.4%)
Short of Breath 8 (13.8%)
Night Sweats 6 (10.3%)
Cough 6 (10.3%)
Rash 6 (10.3%)
Oral Ulcers 6 (10.3%)
Fever 5 (8.6%)
Change in Vision 3 (5.2%)
Bleeding Gums 2 (3.4%)
Dizziness 2 (3.4%)
As seen in Table 3.8, a little over one-third of individuals were asymptomatic at 
diagnosis. The mean CD4 count for asymptomatic individuals was 511 cells/mm3 compared to a 
mean CD4 of 316 cells/mm3 for symptomatic individuals. Of those that were symptomatic, the 
most common symptoms were swollen lymph nodes, weight loss, fatigue, thrush and shortness 
of breath. Other symptoms included night sweats, cough, rash, oral ulcers, fever, change in 
vision, bleeding gums and dizziness. As 15.5% of individuals also had syphilis, some of these 
symptoms (eg. rash and oral ulcers) may be due to their syphilis infection rather than HIV alone.
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Table 3.9:  Disease Stage at HIV Diagnosis
A1 (asymptomatic, CD4 >500) 14 (24.1%)
A2 (asymptomatic, CD4 200-499) 12 (20.7%)
A3 (asymptomatic, CD4 <200) 3 (5.2%)
B1 (symptomatic, CD4 >500) 4 (6.9%)
B2 (symptomatic, CD4 200-499) 6 (10.3%)
B3 (symptomatic, CD4 <200) 10 (17.2%)
C3 (AIDS indicator conditions) 8 (13.8%)
Table 3.9 shows where the individuals fell in the CDC Disease Staging System [41] 
including whether or not they were asymptomatic, symptomatic, or had an AIDS-Indicator 
Condition. From Table 3.9 we can see that the most common categories were A1 (24.1%), A2 
(20.7%) and B3 (17.2%).
28
3.2 – Qualitative Study
Of the 58 individuals diagnosed with HIV in NL between 2006 and 2016, 10 (17.2%) 
agreed to participate in an interview, all of which were MSM. While the sample size was fairly 
small, there were no more individuals we could ask who were eligible for an interview.  
However, data saturation is believed to have been met as each theme was mentioned in at least 
two interviews. All 10 were men who have sex with men. The mean CD4 count at diagnosis 
among the interviewees was 620 cells/mm3 (range 56-1408). There was not a significant 
difference in CD4 count at diagnosis in the interview population compared to the whole 
population (p=0.086). The list of themes derived in this study can be found in table 3.10.
Table 3.10: Themes Derived from HIV Interviews
Themes from Interviews
Number of Interviews 
Where Theme was  
Discussed
Theme 1: Stigma Surrounding HIV and testing 8 (80%)
Theme 2: Interactions with the Healthcare System (Positive and 
Negative)
7 (70%) for positive 
and negative 
interactions each
Theme 3: “It Can’t Happen to Me” 7 (70%)
Theme 4: Fear of the Diagnosis 6 (60%)
Theme 5: The General NL Population is Uneducated about HIV 6 (60%)
Theme 6: NL Lacks Adequate Support for People with HIV 4 (40%)
Theme 7: NL Requires a Broader Range of HIV Testing 4 (40%)
Theme 8: Some People are no longer Afraid of HIV 4 (40%)
Theme 9: NL has a Drug Problem in the Gay Community 2 (20%)
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Theme 1: There is a Stigma Surrounding HIV and Testing
The stigma surrounding HIV was brought up in almost all interviews. Stigma was 
mentioned in both the context of getting the HIV test and after the men had been diagnosed HIV-
positive. 
“But I know when you’re sitting in the waiting room and there’s multiple clinics going on and 
you’re waiting there…It goes through my mind sometimes when I’m sitting there and I think 
“Now am I going to run into anyone I know here now and they’re going to be coming out when 
I’m going in?” (participant 5)
“You were almost wishing that it had been cancer because with cancer it’s more accepted in 
society and with this diagnosis, it’s so taboo and so looked down upon. You don’t realize how 
badly you will be judged”. (participant 3)
“Some guys it’s no big deal, some guys will immediately stop talking to you, some guys will be 
rude and say “Oh god, I’m not…” you know, so I guess people associate the HIV and the STI 
with, I don’t know, just dirty or whatever the word is”. (participant 5)
Theme 2: Interactions with the Healthcare System
Many individuals mentioned having negative interactions with the healthcare system 
during testing and while receiving news of their HIV diagnosis.
“On three separate times while getting tested they asked “Are you an intravenous drug user?” 
and of course I said no, and there was twice on two different encounters where actually one guy 
picked my arm up and he was going all over it and my knuckles and said to the other guy “I 
can’t find any puncture marks”. And I was like “Okay, you’re being a complete shithead … 
From the front counter to the doctors the attitude is very, very poor. I keep telling people don’t 
go to that clinic”.  (participant 2)
“I went to go get tested and my doctor said “nah, you don’t need to get tested for that you look 
fine”. (participant 10)
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“Because what the doctor told me was “you have AIDS” he didn’t say HIV-positive. I don’t have 
AIDS. I’ve never had AIDS. I have HIV. My CD4 count was never low enough for AIDS.” 
(participant 1)
Another individual stated that he believed he had been tested by his health care provider 
for years which may also show a lack of communication between HCPs and patients.  
 
“It came as a really big surprise and shock because I was under the understanding that my 
family doctor who I had been seeing for the past 15-17 years, when I would go for prostate 
exams or just a physical every year that he would be doing the HIV testing”. (participant 7)
Individuals also discussed positive interactions with the healthcare system, and in 
particular positive interactions with the HIV clinic in St. John’s. Participants noted that the clinic 
was privacy oriented, never judgemental, caring and organized. 
“I’m impressed because they’re very, very privacy oriented and very, very thorough, that’s the 
one thing about them”. (participant 2)
“I talk to (the HIV nurse) on a daily basis because she’s the best. I love her. She’s very good, 
very thorough, very inviting, very sweet person and she doesn’t make you feel uncomfortable”. 
(participant 10)
“But even from the being diagnosed to the follow-up it was seamless for me, it was almost like it 
was all taken care of and I just had to show up which made it really, really easy, I didn’t have to 
think about “Okay, what’s the next step?” They had all that information…”. (participant 5)
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Theme 3: “It Can’t Happen to Me”
When asked if they believed they were at risk for HIV, almost all participants said they 
did not think they were at risk despite being in the high risk category of MSM. Most were aware 
about the risks associated with unprotected anal sex but believed it just could not happen to 
them.
“I was aware because I work in health care, so you are aware but you never think it will happen 
to you…I guess I never thought it would happen to me, and I guess a lot of people do think that 
“Oh that will never happen”, but it do. It’s out there. You just don’t think about it, right? So you 
just go on with life”. (participant 3)
“Because I’ve been (tested) before, I knew how easy it was to access, and maybe just after going 
so many times, it’s like “Well I’ve gone so many times before and it’s always been negative”. 
Why would I bother to keep going?” (participant 5)
Theme 4: Fear of the Diagnosis
Over half the participants noted that the fear of the HIV diagnosis itself was a barrier to 
getting tested as it is believed to still be a death sentence. The fear of criminalization which was 
previously reported in another Canadian study [36] was not brought up as an issue in this 
population. No participants described the fear of diagnosis as being a barrier for themselves, but 
described this as something they were aware of among their friends in the local community.  
“And anyone I talk to, and I’ve talked to guys that I’ve known for years and say, you know, “Do 
you ever go get tested?” and they say “Nah, I haven’t been there in a couple of years” “You 
need to go” “I just don’t wanna go, I don’t want to know” (participant 5)
“No one really wants to go get tested, you know? I think it’s because they’re nervous, they’re 
scared and they just don’t want to know. That’s it. They just don’t want to know. Their nerves go 
to the sky and they’re like “No, okay I’m not going to go get tested” and they’re the ones who 
got it” (participant 10)
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Theme 5: The General NL Population is Uneducated about HIV 
Over half of the participants recounted their own misinformation about HIV and the lack 
of education and awareness among the general population.
“When I was dealing with it I was going through a hard time and didn’t know if I could wash my 
clothes with someone else’s clothes because that’s how much information I was lacking” 
(participant 10)
“I think more education out and about would help people through it more. For the public, even. 
Sometimes I listen to my family members when they’re talking and the subject comes up and they 
don’t know. They’re so uneducated about it, and the comments they make, I just sit there and 
look at them and say “Are you for real?” (participant 3)
Theme 6: NL Lacks Adequate Support for People with HIV
In 40% of interviews, participants complained that NL does not have adequate support 
for people living with HIV in the province. A couple of participants noted they get their support 
from other provinces.
“There’s not a lot of resources around here to talk to someone about it at a certain time. 
Everyone goes home at 5 o’clock time frame and it’s kind of like where to get your 
information and how to get your information… I had to call AIDS Vancouver and talk to one of 
the representatives there about everything that was going on and I made a friend within that 
center that I talked to pretty much on a daily basis. So I don’t talk to anyone around here, I 
speak to someone outside of Newfoundland”. (participant 10)
“When I first found out I was looking for support, and when it comes to this city it’s very hard to 
find group support. There’s none. Zero.” (participant 2)
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Theme 7: NL Requires a Broader Range of HIV Testing
In just under half of the interviews, participants stated how they wish there had been a 
point of care test or how they have friends that could benefit from this test. The idea of waiting 
for the result and fear of needles were two issues brought up.
“And here they don’t have quick testing. I went on holiday and while I was there, we were out 
having lunch at a restaurant, and across the parking lot they were doing HIV testing in an 
ambulance vehicle for people. And I was like: Oh my god, if they only had that in Canada”. 
(participant 3)
“If there was another way of getting people to test without needles. A swab or something like 
that. If that was in place…I know a lot of grown men who are afraid of needles. Something easy 
like pee in a bottle. Something along those lines. It’s the needle that keeps a lot of people away. 
I’ve seen people faint. Very fearful” (participant 1)
Theme 8: Some People are not Afraid of HIV
In a complete contrast to the theme of “Fear of the Diagnosis”, in a little less than half of 
the interviews, participants noted how some people no longer fear HIV and therefore delay 
testing or continue to have unprotected sex. Interestingly, one participant recounted how his 
friend purposely became infected with HIV.
“Everybody knows that most STIs are curable anyway and HIV now is manageable so like I 
really don’t think many people care that much. A lot of my friends who are HIV-positive have sex 
parties and will tell people beforehand their …and everybody goes” (participant 8)
“I think people are thinking well that’s not a death sentence anymore so I don’t have to be 
careful” (participant 1)
“…he said he got intentionally infected. I’ve come across individuals who are like this. Who said 
they want to get it out of the way because they’re very, very sexual, which is what he is… He told 
me that he was very happy that he had become infected. He said “…I’m so sexual in nature and 
so involved in the drugs and everything else”. He just wanted to get it out of the way” 
(participant 2)
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Theme 9: NL has a Drug Problem in the Gay Community
Two participants (20%) noted how the gay community in St. John’s has been using more drugs 
over the last few years and believe this may result in riskier behavior.
“Within the gay world, you will find there has been a lot of drug use and it has gotten worse. The 
younger ones are very involved with drugs. They’ll use that term “party and play”. Crystal meth 
and molly are big ones…the drug thing is phenomenal. It’s getting worse. It’s getting really, 
really worse” (participant 2)
“Probably the drugs too are a big deal. A lot of gay guys are using drugs. It’s really big now. 
Crystal meth, molly, coke, anything like that. So at night everyone is looking for sex and don’t 
care about using condoms. There’s a lot of drugs and alcohol on the go, I guess, too” 
(participant 8)
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4.0 - Discussion 
4.1 – Quantitative Findings and Implications
Overall, 36.2% of our patients received a late diagnosis (CD4 count < 200 cells/mm3), 
and 17.2% had a CD4 count of 30 cells/mm3 or less. Of the Canadian studies available, NL has a 
higher prevalence of late diagnosis despite using a stricter definition of a late diagnosis (<200 
cells/mm3 at diagnosis) compared to more lenient definitions such as “<200 cells/mm3 at 
diagnosis or an AIC 12 months after diagnosis” which was used in other studies. Even with the 
stricter definition, our prevalence was 36.2% compared to the highest of 30% in Manitoba using 
the criteria of <200 cells/mm3 when entering into care [20]. More studies are needed, however, to 
determine the prevalence in other provinces without published surveillance data.
 The only statistically significant demographic factor that appears to predict late diagnosis 
was sexual orientation, with heterosexual individuals more likely to present later than MSM. One 
possible explanation for this could be that MSM may be tested more often, as their sexual 
orientation is a known risk factor. Support for this possibility is that MSM had significantly more 
HIV tests than heterosexual individuals (p=0.036). Furthermore, healthcare practitioners may be 
more inclined to suggest HIV testing for patients with this risk factor. More emphasis needs to be 
put on encouraging “never before tested” sexually active heterosexual individuals to get tested 
for HIV and normalizing testing so HIV will no longer be considered a “gay disease”. While it 
would cost more money upfront to offer testing to these men, avoiding a late diagnoses could 
save money in the long run. There was no significant difference in gender, age, residence and 
employment. As the vast majority of individuals were male, however, it may be justified to 
recommend HIV testing in all sexually active middle-aged men who have never before been 
36
tested. From our study, the most likely to present with a late diagnosis of HIV are heterosexual 
male individuals who are middle-age and live in urban NL. Frequent visits to the ER and never 
previously being tested for HIV would also be a good reason to suggest HIV testing.   
The fact that for 67.2% of people their first HIV test was the one where they were 
diagnosed HIV-positive also implies Newfoundlanders are not accessing routine testing. The 
mean age of individuals at diagnosis was 40.6 years, which leaves many years of previous sexual 
activity during which no testing occurred. Furthermore, 84.5% of individuals had not been tested 
within a year prior to diagnosis, when frequent sexual activity and therefore HIV transmission 
may have occurred. For this reason HIV testing must be normalized and become part of a 
healthcare routine. 
Over 60% of HIV tests were suggested by a healthcare practitioner (HCP), however, 
there may have been many opportunities to recommend testing sooner. The mean number of 
healthcare contact visits in the five years before diagnosis was 13.7. This number includes clinic 
visits, ER visits and hospital admissions. This does not include family physician visits, indicating 
that the mean number of visits may be higher than 13.7. Individuals with a late diagnosis were 
infected with HIV years before diagnosis, meaning there was a long period during which testing 
could have been performed. 
Our study also suggests missed opportunities for other STI testing, as testing for 
Chlamydia and Gonorrhea at the same time as HIV testing only occurred in one-third of cases. It 
is important to note that over one-third of individuals were asymptomatic at the time of HIV 
diagnosis with CD4 counts as low as 85 cells/mm3. This indicates HCPs should not just offer 
HIV testing to individuals presenting with HIV-specific symptoms alone, or they may miss HIV-
positive asymptomatic individuals. 
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One heterosexual male was diagnosed with a CD4 count of 16 cells/mm3 with the AIDS-
Indicator Condition of Pneumocystis Pneumonia (PCP). In the eight months prior to his 
diagnosis, he had been to the ER five times complaining of chest congestion, cough, shortness of 
breath, weakness, fatigue, inability to sleep, feeling generally unwell, sore throat and swollen 
tongue. There was no mention of HIV in the first four visits. On his fifth visit, five months 
before he was diagnosed, in the physician’s notes it mentions how the symptoms could be due to 
HIV and how the patient had not been tested within the past seven years, however, no test was 
performed. The patient was sent home and was not diagnosed HIV-positive until five months 
later, when he presented to the ER again with PCP.
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4.2 – Qualitative Findings and Implications
The only individuals who agreed to participate in an interview were MSM. This 
observation may demonstrate increased awareness and comfort in discussing HIV among the 
MSM population compared to the heterosexual population.
Theme 1: There is a Stigma Surrounding HIV and Testing
 Stigma was the main discussion point during the interviews. Many individuals had only 
told select family and friends about the diagnosis, and were concerned about others finding out 
they were HIV-positive, due to the stigma attached. A common theme involving stigma was that 
individuals may feel uncomfortable in the waiting room of an STI clinic because others would 
think they were promiscuous. This stemmed from the idea that if someone had a low number of 
sexual partners, they would not need to get tested for STIs. This clearly demonstrates the fact 
that STI testing must be normalized. One solution to stigma as a barrier to HIV testing is to offer 
anonymous testing. Currently in NL anonymous testing is available upon request but is not part 
of the official guidelines for the province [39]. It is quite possible that many individuals are not 
aware that they can request anonymous HIV testing and instead choose not to get tested at all.
Furthermore, some individuals noted that since NL is a small province, everyone seems 
to know everyone, or at least knows someone who knows you, especially in small towns. The 
idea that everyone knows you or knows someone that knows you was part of this waiting room 
fear. The “everyone knows everyone” fear was also mentioned as a reason for reluctance to 
disclose HIV status. One participant from a small town stated how everyone in his town knows 
of him as the “guy with HIV” because of this gossiping. The idea that only “dirty” people 
contract HIV was also brought up in interviews, further amplifying the stigma. In a 2010 study in 
Paris, it was found that individuals determined to have a stigma towards people with HIV based 
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on their response to questions (eg. Would you have a meal at their home?) were significantly less 
likely to have ever been tested (p<0.0001 for men and p=0.0002 for women) [42]. Another study 
in the United States involving black MSM found that the men with a high internalized stigma 
towards HIV based on their agreement with statements like “I am concerned that if I go to an 
AIDS organization someone I know might see me”, were less likely to get tested for HIV though 
this did not quite reach statistical significance (p=0.06) [43].  
Theme 2: Interactions with the Healthcare System
The next major theme in the interviews was interactions with the healthcare system. One 
individual asked his HCP for a requisition for an HIV test and was denied because the doctor 
said he looked healthy. As many individuals are asymptomatic at diagnosis, screening using the 
presence of symptoms as an indicator is not an appropriate approach to testing. Furthermore, this 
man was homosexual and had had unprotected sex with various partners and knew he was at 
risk. In this case the physician could have explored the reasons why the test was requested or 
they may have been unaware of the fact that individuals can be HIV-positive and be 
asymptomatic. In a study looking at HIV testing among young MSM in Detroit, individuals 
whose HCP discussed HIV prevention with them were significantly more likely to have been 
tested for HIV compared to individuals who had never discussed HIV with their HCP (p<0.001) 
[44]. This indicates HCPs should openly discuss HIV prevention and HIV testing with their 
patients. Many other individuals said they went to get tested for HIV and felt they were judged or 
treated poorly by the person doing the testing. One man stated he left one clinic crying because 
of the way he was treated. If individuals believe they are being judged or otherwise treated badly 
by a HCP, they may be unlikely to return for another test. In a Los Angeles study, for example, 
approximately one fourth of the sample reported perceived stigma from a health care provider 
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regarding HIV and this stigma was found to be associated with a lower access to care (OR=3.29) 
[45]. To combat this, a HIV stigma scale for health care providers in North America has been 
developed and assessed using nursing and medical students across Canada [46]. The scale 
consists of questions used to measure stigma by healthcare providers (eg. HIV (+) patients make 
me uncomfortable) which can then be used to provide appropriate training to reduce the HCP’s 
stigma [46]. Furthermore, they may tell their friends of the bad experience and deter them from 
going as well. One individual said during the interview that he tells all his friends to avoid a 
certain clinic for the way he was treated. An individual who is willing to get tested for HIV who 
is treated with respect may be more likely to get tested again in the future. Many participants also 
noted that their family doctor gave them no information about HIV once they were diagnosed 
and told them they were positive in a less than ideal way. One individual said the doctor simply 
passed him a paper with the words “HIV-reactive” circled in red pen. Another individual 
reported his family doctor was mad at him for being HIV-positive. Many participants also noted 
they were convinced they were dying until they met with the HIV clinic.
 A more positive healthcare interaction was noted when the question “Who provides care 
for your HIV?” was asked during the interview. This led to 70% of individuals praising the team 
members and giving a narrative about how the clinic has positively impacted their life. While 
this would not affect HIV testing, it is nice to know there is a good resource for people that test 
positive for HIV.
Theme 3: “It Can’t Happen to Me”
The next major theme was the idea that “it can’t happen to me”. Many individuals knew 
the risks involved with unprotected anal sex and knew about HIV but were under the impression 
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that they would not get it. Many participants noted how they would ask if their partner was 
“clean” and if they said yes then it was safe to not use a condom. Unfortunately, many 
individuals that are HIV-positive are unaware of their status. Furthermore, the idea that they 
haven’t gotten any STIs over the years while having unprotected sex led to a false feeling of 
security. The number of sexual partners was also thought to be associated with HIV. One 
participant noted that he was shocked that he had gotten HIV because he had only had two 
sexual partners in the previous year. In a study in 2007 in the United states, 936 MSM who had 
never been tested for HIV indicated that they were not at risk for HIV as the number one reason 
for not having been tested [47]. Although MSM is a known risk factor for HIV, many individuals 
did not think they were at risk and this correlated with avoiding testing.
 It is important that emphasis is placed on the idea that HIV can happen to anyone, and not 
getting STIs in the past does not mean it cannot happen in the future. Furthermore, it should be 
made clear that although an individual may only have a few sexual partners, those partners may 
have had numerous partners before them and may have exposed them to HIV and other STIs.
Theme 4: Fear of the Diagnosis
The next main theme and barrier to testing is the fear of the HIV diagnosis itself. The 
participants described this fear as something they were aware of among their friends in the local 
community instead of a barrier they faced themselves. It is possible that this sample was atypical 
of the general population or they were unwilling to admit that they experienced this fear 
themselves. Many individuals may be reluctant to get tested because they are afraid of finding 
out they are HIV-positive. This may be partially because of the stigma attached to HIV and due 
to the fear that HIV is a death sentence. In many interviews the participants said they believed 
HIV was a death sentence before they were diagnosed and many thought they were dying up 
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until when they met with the HIV clinic. More education is needed for these reasons. An 
Australian study in 2012 involving 1093 MSM further demonstrated how fear of an HIV 
diagnosis can impact testing [48]. In this study, 40.2% of people who had never been tested 
indicated fear of a positive result as a barrier to testing for them. This was significantly higher 
(p<0.01) than individuals who had been tested previously in which 26.0% indicated they were 
scared of receiving a positive diagnosis [48]. If the public is made aware about HIV and 
misconceptions about HIV are eliminated, the stigma may decline. Furthermore, if the public is 
educated about how HIV is no longer a death sentence and is classified as a chronic disease, 
perhaps more people would be willing to get tested as they know there are treatments available. 
Theme 5: The General NL Population is Uneducated about HIV 
The previous theme of fear of the diagnosis ties in perfectly with the next theme that the 
general population of Newfoundlanders are uneducated about HIV. For example, some 
individuals shared how they were uneducated about HIV transmission. One individual believed 
that only the receptive partner during intercourse could become HIV-positive, while another 
believed HIV could not be contracted through oral sex. While the risk is much lower for the 
penetrative partner and performing oral sex, it is still possible to contract HIV this way. Another 
participant believed he had been tested for HIV for years as he had been getting yearly 
bloodwork and assumed HIV was part of the annual checkup. Other individuals shared their own 
misconceptions about HIV after they had been diagnosed. One individual recounted his fear of 
being around small children after he was diagnosed as he was afraid that they would somehow 
contract HIV through casual contact. The misconception about HIV being transmitted through 
casual contact was also brought up by other participants referring to negative encounters with 
HIV-negative individuals. With more education to the general public regarding what it means to 
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be HIV-positive and how the virus is transmitted, there may be less stigma, STI testing may 
become more normalized, and individuals may be less afraid to be diagnosed HIV-positive.   
Theme 6: NL Lacks Adequate Support for People with HIV
While the HIV clinic had excellent reviews, approximately half of the participants still 
said NL lacks adequate resources for people with HIV. Many participants noted how they felt 
completely alone and helpless from the time they were first diagnosed until they had their 
appointment with the HIV clinic. As there is a stigma attached to HIV, many felt they could not 
confide in family and friends and even talking to someone that deals with general mental health 
issues was too intimidating as they were too afraid to share their diagnosis. Even after meeting 
with the HIV clinic, some individuals still had many questions and felt that after 5pm there was 
no one they could talk to about their concerns. Perhaps an HIV or STI crisis line or other service 
would be helpful in addressing this issue.
Theme 7: NL Requires a Broader Range of HIV Testing
The next theme inferred from the interviews is that NL would benefit from other testing 
methods including a point of care (POC) test. A few reasons for why other testing options would 
be beneficial are that some individuals fear needles or do not like bloodwork, there is too much 
time between the test and the result which may make people worry, and the need to return for 
test result is inconvenient. Anonymity of results may also attract more individuals to test for 
HIV. In the 2012 Australian study looking at barriers to HIV testing in 1093 MSM, the 
individuals who had never been tested were significantly more likely to say having blood drawn 
was a barrier to testing than those who had been tested in the past (p=0.02) [48]. From this study 
it appears that a fear of bloodwork does impact likelihood of testing and a different method of 
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testing would be beneficial. Currently a POC HIV screening finger-prick blood test is being 
offered in two locations in NL as part of another research study so perhaps more individuals will 
take advantage of this service. Our data suggests there is value in a POC test and we support 
making this more widely available after the current research study concludes. 
Theme 8: Some People are not Afraid of HIV
In a direct contrast to the theme involving the fear of testing positive for HIV, another 
theme brought up was that some individuals no longer fear HIV as it is quite treatable. For this 
reason, we must be careful how educational campaigns are marketed. On one hand, we want to 
reduce the fear that HIV is a death sentence, and on the other hand we must ensure that people 
are still concerned about HIV enough to get tested as one means of reducing transmission in the 
community. It must also be made clear that HIV can be fatal if not treated, but many treatment 
options are available.
Theme 9: NL has a Drug Problem in the Gay Community
Finally, one last theme was that there may be a drug problem in the gay community. 
While this was only brought up in 2 (20%) interviews, no question regarding drug use had been 
asked during the interview so for this to be brought up independently twice may indicate a real 
problem. Furthermore, both individuals listed the same drugs being used (i.e. crystal meth and 
“molly” – a form of MDMA). This could be an important issue for HIV transmission as many 
individuals under the influence of these drugs may be involved in riskier sexual behaviour or 
share drug equipment though this association is still unclear [49]. 
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4.3 – Study Limitations
Limitations of this study include a retrospective chart review, a small sample size and 
possible recall bias. Our retrospective study design may have missed data or conclusions because 
these were not available in the medical record. Perhaps some individuals had more symptoms at 
diagnosis but they were not recorded, for example. Furthermore, some information relies on the 
honesty and recall of the individuals. When asked if they were alcohol users, for example, 31% 
said they did not use alcohol at all. It is possible that some individuals may not have been honest 
about their alcohol use. Furthermore, sexuality can be a complex subject, so some individuals 
may describe themselves as heterosexual but may have occasional sex with men thus putting 
them at higher risk. For the qualitative study, some individuals may have forgotten certain 
experiences as they had been diagnosed up to ten years prior to the interview. Over long periods 
of time it would be quite easy to forget exactly how the physician acted or what they said the day 
they were diagnosed. Furthermore, there was a selection bias for the interviews. All the 
individuals that agreed to participate in an interview were MSM and their responses may not 
generalize to everyone diagnosed with HIV. The mean CD4 count of those who agreed to an 
interview was also higher than those who did not, which may mean that these individuals faced 
less barriers to HIV testing. 
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4.4 – Future Studies
Further research that would add to the knowledge around uptake of HIV testing would 
include interviewing different groups of individuals or handing out surveys regarding testing.  
Our study population included only 2 IVD users and 5 women so it would be important to 
determine if there really are very few cases of IVDU and women with HIV or if they are not 
being tested. A study that would be interesting to conduct in NL would be asking people who 
have never been tested for HIV the reasons why they have never been tested. Perhaps specific 
age groups and risk groups could be targeted in this study. Another study would be to interview 
people that have tested negative for HIV and ask them the reasons why they chose to get tested 
and ask them to discuss their testing experience. These studies may also suggest ways to increase 
HIV testing. Currently there is a study ongoing in NL involving a POC test which will be 
interesting to see if more individuals chose to get tested through this method, and may be 
grounds to introduce POC testing permanently. Further studies could also analyze the impact of 
drug use in the gay community and offer education or an intervention to address this potential 
problem. A study surrounding an educational intervention addressing the issue that some 
individuals no longer fear HIV could also be implemented. 
4.5 - Possible Testing Interventions
Based on the results of our study, new policy to promote HIV testing may reduce the 
incidence of late diagnosis. Universal testing at each healthcare contact is expensive and the pre-
test probability among the general population is extremely low.  However, testing based on local 
risk factors may be more efficient.  ER patients automatically selected based on demographics 
such as age, sex, urban address, or absence of previous HIV test results could be notified to the 
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attending physician as at risk of late diagnosis of HIV.  This automated notification could inform 
the physician that the test will be performed unless the lab is notified that the patient refuses. 
Opt-out testing in the ER has been successfully implemented in other jurisdictions as patients are 
diagnosed earlier and linked to care [50,51]. With opt-out testing, more individuals are willing to 
accept an HIV test [52]. Healthcare providers should also talk openly to their patients about the 
risks involved with unprotected sex and normalize the discussion of HIV and testing. If an 
individual asks for an HIV test, they should not be denied a test. Furthermore, it may be useful 
for HCPs to offer testing to middle-aged sexually active heterosexual men who have never 
before been tested.
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5.0 - Conclusion
Many individuals are getting tested late for HIV and presenting with low CD4 counts. 
While there are few studies in which to compare, it appears that NL has a higher prevalence of 
late diagnosis than other Canadian provinces. There was frequent healthcare contact prior to 
diagnosis which may represent missed opportunities for HIV testing.  This may have been 
prevented if HIV testing was a more routine testing procedure.  Furthermore, education of 
physicians may reduce delayed HIV diagnosis. Physicians must recognize that HIV occurs in 
heterosexual individuals as well as MSM, and that many individuals with HIV may be 
asymptomatic. As well, stigma is a problem in NL and this must be addressed through 
educational campaigns normalizing HIV testing and what it means to be HIV-positive. 
Individuals must be made aware that HIV is no longer a “death sentence” if treated but can be 
fatal if left untreated. However, educational campaigns should not downplay the severity of HIV 
as some individuals were noted to no longer fear HIV and avoid testing for this reason. 
Educational campaigns may also be beneficial in encouraging heterosexual men to get tested for 
HIV.
49
6.0 – References
[1] Public Health Agency of Canada, “Summary: Estimates of HIV Incidence, Prevalence        
and Proportion Undiagnosed in Canada, 2014,” 2014.
[2] Public Health Agency of Canada, “Canadian Guidelines on Sexually Transmitted 
Infections”. Retrieved July 7, 2017 from http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-
ldcits/section-5-8-eng.php. 2016.
[3] P. G. Farnham, C. Gopalappa, S.L. Sansom, A.B. Hutchinson, J.T. Brooks, P.J. Weidle, 
V.C. Marconi, and D. Rimland. “Updates of Lifetime Costs of Care and Quality-of-Life 
Estimates for HIV-Infected Persons in the United States,” JAIDS Journal of Acquired 
Immune Deficiency Syndrome, vol. 64, no. 2, pp. 183–189, 2013.
[4] H. Jiang, N. Xie, J. Liu, Z. Zhang, L. Liu, Z. Yao, X. Wang, and S. Nie. “Late HIV 
Diagnosis:Proposed Common Definitions and Associations With Short-Term Mortality,” 
Medicine (Baltimore)., vol. 94, no. 36, p. e1511, 2015.
[5] The Antiretroviral Therapy Cohort Collaboration, “Causes of Death in HIV-1-Infected 
Patients Treated with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 
HIV Cohort Studies,” Clinical Infectious Diseases., vol. 50, pp. 1387–1396, 2010.
[6]      Association of Medical Microbiology and Infectious Diseases Canada, “The Use of Early 
Antiretroviral Therapy in HIV-infected Persons,” pp. 1–21, 2016.
[7] J. A. C. Sterne, M. May, D. Costagliola, F. de Wolf, A.N. Phillips, R. Harris, M. J. Funk , 
R. B. Geskus, J. Gill, F. Dabis, J. M. Miró, A. C. Justic, B. Ledergerber, G. Fätkenheuer, 
R. S. Hogg, A. D. Monforte, M. Saag, C. Smith, S. Staszewski, and M. Egger. “Timing of 
initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative 
analysis of 18 HIV cohort studies". Lancet. Apr 18; 373(9672): 1352–1363, 2009
 
[8] A. Hänsel, H. C. Bucher, R. Nüesch, M. Battegay. “Reasons for Discontinuation of First 
Highly Active Antiretroviral Therapy in a Cohort of Proteinase Inhibitor - Naive HIV-
Infected Patients,” Journal for Acquired Immune Deficiency Syndrome,26:191-197, 2001.
[9] G. Marks, N. Crepaz, J. W. Senterfitt, and R. S. Janssen, “Meta-analysis of high-risk 
sexual behavior in persons aware and unaware they are infected with HIV in the United 
States - Implications for HIV prevention programs,” Journal of Acquired Immune 
Defiiency Syndrome, vol. 39, no. 4, pp. 446–453, 2005.
[10] H. B. Krentz and M. J. Gill, “The Direct Medical Costs of Late Presentation (<350/mm) of 
HIV Infection over a 15-Year Period,” AIDS Research & Treatment, vol. 2012, p. 757135, 
2012.
50
[11]    Public Health Agency of Canada, “Human Immunodeficiency Virus - HIV Screening and 
Testing Guide.” 2014.
[12]   S. Wertheimer, “Women and HIV Testing in Canada : Barriers and Recommendations as 
Identified by Service Providers,” Canadian AIDS Society pp. 1–19, 2011.
[13] L. M. Williamson, P. Flowers, C. Knussen, and G. J. Hart, “HIV testing trends among gay 
men in Scotland, UK (1996-2005): implications for HIV testing policies and prevention,” 
Sexual Transmission and Infection, vol. 85, no. 7, pp. 550–554, 2009.
[14] R. Bath, R. O’Connell, M. Lascar, R. Ferrand, S. Strachan, N. Matin, I Bassnet, C Orkin, 
“TestMeEast: a campaign to increase HIV testing in hospitals and to reduce late 
diagnosis,” AIDS Care, vol. 28, no. 5, 2016.
[15] A. J. Mutch, C. Lui, J. Dean, L. Mao, J. Lemoire, J. Debattista, C. Howard, A. Whittaker 
and L. Fitzgerald, “Increasing HIV testing among hard-to-reach groups: examination of 
RAPID, a community-based testing service in Queensland, Australia,” BMC Health 
Service Research, vol. 17, no. 1, p. 310, 2017.
[16] A. Antinori, T. Coenen, D. Costagiola, N. Dedes, M. Ellefson, J. Gatell, E. Girardi, M. 
Johnson, O. Kirk, J. Lundgren, A. Mocroft, A. d’Arminio Monforte, A. Phillips, D. 
Raben, J.K. Rockstroh, C. Sabin, A. Sonnerborg and F. de Wolf . “Late presentation of 
HIV infection: A consensus definition,” HIV Medicine, vol. 12, no. 1, pp. 61–64, 2011.
[17] Center for Disease Control, “AIDS-Defining Conditions” MMWR 57(RR10);9, 2008.  
[18] British Columbia Centre for Disease Control, “HIV in British Columbia: Annual 
Surveillance Report 2014,” BC Center for Disease Control, pp. 1–45, 2015.
[19] Manitoba HIV Program, “Manitoba HIV Report 2015,” 2015.
[20] D. Jaworsky, L. Monette, J. Raboud, D. O’Brien-Teengs, C. Diong, S. Blitz, S. B. Rourke, 
M. R. Loutfy. “Comparison of late HIV diagnosis as a marker of care for Aboriginal 
versus non-Aboriginal people living with HIV in Ontario,” Canadian Journal of Infectious 
Disease & Medical Microbioly, vol. 23, no. 4, pp. 96–102, 2012.
[21] H. I. Hall, J. Halverson, D. P.Wilson, B. Suligoi, M. Diez, S.Le Vu, T. Tang, A. 
McDonald, L. Camoni, C. Semaille, C. Archibald. “Late diagnosis and entry to care after 
diagnosis of human immunodeficiency virus infection: A country comparison,” PLoS 
One, vol. 8, no. 11, 2013.
[22] NSHW, “Surveillance Report on HIV/AIDS in Nova Scotia: 1983 to 2011,” 2012.
51
[23] A. Mocroft et al., “Late presentation for HIV care across Europe: Update from the 
collaboration of observational HIV epidemiological research europe (COHERE) study, 
2010 to 2013,” Eurosurveillance, vol. 20, no. 47, 2015.
[24] S. Ellis, H. Curtis, and E. L. C. Ong, “HIV diagnoses and missed opportunities. Results of 
the British HIV Association (BHIVA) national audit 2010,” Clinical Medicine vol. 12, no. 
5, pp. 430–434, 2012.
[25] C. Agustí, A. Montoliu, J. Mascort, R. Carrillo, J. Almeda, J. M. Elorza, M. Aragón, J. 
Casabona, “Missed opportunities for HIV testing of patients diagnosed with an indicator 
condition in primary care in Catalonia, Spain,” Journal of Sexually Transmitted 
Infections,2015-052328, 2016.
[26] M. Helleberg, F. N. Engsig, G. Kronborg, A. L. Laursen, G. Pedersen, O. Larsen, L. 
Nielsen, J. Jensen, J. Gerstoft and N. Obel, “Late presenters, repeated testing, and missed 
opportunities in a Danish nationwide HIV cohort,” Scandinavian Journal of Infectious 
Diseases, vol. 44, no. 4, pp. 282–288, 2012.
[27] J. H. Nakao, D. E. Wiener, D. H. Newman, V. L. Sharp, and D. J. Egan, “Falling through 
the cracks? Missed opportunities for earlier HIV diagnosis in a New York City Hospital.,” 
Int. Journal of STD & AIDS, vol. 25, no. 12, pp. 887–93, 2014.
[28] M. Arya, S. Patel, D. Kumar, M. Y. Zheng, M. A. Kallen, R. L. Street, Jr.,  K. Viswanath,  
and T. P. Giordano, “Why Physicians Don’t Ask : Interpersonal and Intrapersonal Barriers 
to HIV Testing — Making a Case for a Patient-Initiated Campaign,” HIV Testing & 
Diagnosis, vol. 15, no. 4, pp. 306–312, 2016.
[29] I. K. Joore, S. L. van Roosmalen, J. E. van Bergen, and N. van Dijk, “General 
practitioners barriers and facilitators towards new provider-initiated HIV testing 
strategies: a qualitative study,” International Journal of STD & AIDS, vol. 0, no. 0, p. 
956462416652274, 2016.
[30] C. V. Johnson, M. J. Mimiaga, S. L. Reisner, R. VanDerwarker, and K. H. Mayer, 
“Barriers and Facilitators to Routine HIV Testing: Perceptions from Massachusetts 
Community Health Center Personnel,” AIDS Patient Care STDS, vol. 25, no. 11, pp. 647–
655, 2011.
[31] D. G. Partridge, P. Collini, and M. W. McKendrick, “HIV testing: the boundaries. A 
survey of HIV testing practices and barriers to more widespread testing in a British 
teaching hospital,” International Journal of STD & AIDS, vol. 20, no. 6, pp. 427–428, 
2009.
[32] P. B. Wright, G. M. Curran, K. E. Stewart, and B. M. Booth, “A qualitative analysis of 
provider barriers and solutions to HIV testing for substance users in a small, largely rural 
southern state,” Journal of Rural Health, vol. 29, no. 4, pp. 420–431, 2013.
52
[33] E. M. Simmons, M. J. Brown, K. Sly, M. Ma, M. Y. Sutton, and E. McLellan-Lemal, 
“Barriers and facilitators to HIV testing in primary care among health care providers,” 
Journal of National Medical Association, vol. 103, no. 1943–4693 (Print), pp. 432–438, 
2011.
[34] J. E. Mill, R. C. Jackson, C. A. Worthington, C. P. Archibald, T. Wong, T. Myers, T. 
Prentice and S. Sommerfeldt, “HIV testing and care in Canadian Aboriginal youth: a 
community based mixed methods study.,” BMC Infectious Diseases, vol. 8, p. 132, 2008.
[35] A. I. Scheim and R. Travers, “Barriers and facilitators to HIV and sexually transmitted 
infections testing for gay, bisexual, and other transgender men who have sex with men,” 
AIDS Care, vol. 0, no. 0, pp. 1–6, 2016.
[36] P. O’Byrne, J. Willmore, A. Bryan, D. S. Friedman, A. Hendriks, C. Horvath, D. 
Massenat, C. Bouchard, R. S. Remis and V. Etches, “Nondisclosure prosecutions and 
population health outcomes: examining HIV testing, HIV diagnoses, and the attitudes of 
men who have sex with men following nondisclosure prosecution media releases in 
Ottawa, Canada.,” BMC Public Health, vol. 13, no. 1, p. 94, 2013.
[37] S. Holtzman, L. Landis, Z. Walsh, E. Puterman, D. Roberts and K. Saya-Moore, 
“Predictors of HIV testing among men who have sex with men: A focus on men living 
outside major urban centres in Canada,” AIDS Care, vol. 28, no. 6, pp. 705–711, 2016.
[38] K. Bolsewicz,  a Vallely, J. Debattista,  a Whittaker, and L. Fitzgerald, “Factors impacting 
HIV testing: a review - perspectives from Australia, Canada, and the UK.,” AIDS Care, 
vol. 121, no. December, pp. 1–11, 2014.
[39]    Public Health Agency of Canada, “HIV/AIDS Epi Updates - July 2010 - Chapter 3: HIV 
Testing and Surveillance Systems in Canada,” 2010. 
[40] “The APPROACH Study,” 2017. [Online]. Available: 
http://www.mun.ca/pharmacy//research/approachstudy.php.
[41]    Centers for Disease Control and Prevention, “Terms, Definitions, and Calculations Used 
in CDC HIV Surveillance Publications,” Center for Disease Control, no. May, pp. 1–3, 
2014.
[42] V. Massari, A. Lapostolle, M.-C. Grupposo, R. Dray-Spira, D. Costagliola, and P. 
Chauvin, “Which adults in the Paris metropolitan area have never been tested for HIV? A 
2010 multilevel, cross-sectional, population-based study,” BMC Infectious Diseases, vol. 
15, no. 1, p. 278, 2015.
[43] S. B. Mannheimer, L. Wang, L. Wilton, H.V. Tieu, C. del Rio, S. Buchbinder, S. Fields, 
S. Glick, V. Cummings, S.H. Eshleman, B. Koblin, and K.H. Mayer “Infrequent HIV 
Testing and Late HIV Diagnosis Are Common Among a Cohort of Black Men Who Have 
Sex With Men in 6 US Cities,” JAIDS Journal of Acquired Immune Deficiency Syndrome, 
vol. 67, no. 4, pp. 438–445, 2014.
53
[44] S. Meanley, A. Gale, C. Harmell, L. Jadwin-Cakmak, E. Pingel, and J. A. Bauermeister, 
“The role of provider interactions on comprehensive sexual healthcare among young men 
who have sex with men,” AIDS Education and Prevention, vol. 27, no. 1, pp. 15–26, 2015.
[45] D. A. Mackellar, S. Hou, C. C. Whalen, K. Samuelsen, T. Sanchez, A. Smith, D. Denson, 
A. Lansky and P. Sullivan “Reasons for not HIV testing, testing intentions, and potential 
use of an over-the-counter rapid HIV test in an internet sample of men who have sex with 
men who have never tested for HIV.,” Sexually Transmitted Diseases, vol. 38, no. 5, pp. 
419–28, 2011.
[46] J. J. Kinsler, M. D. Wong, J. N. Sayles, C. Davis, and W. E. Cunningham, “The Effect of 
Perceived Stigma from a Health Care Provider on Access to Care Among a Low-Income 
HIV-Positive Population,” AIDS Patient Care STDS, vol. 21, no. 8, pp. 584–592, 2007.
[47] A. C. Wagner, T. A. Hart, K. E. McShane, S. Margolese, and T. A. Girard, “Health Care 
Provider Attitudes and Beliefs About People Living with HIV: Initial Validation of the 
Health Care Provider HIV/AIDS Stigma Scale (HPASS),” AIDS Behaviour., vol. 18, no. 
12, pp. 2397–2408, 2014.
[48] D. P. Conway, M. Holt, D. L. Couldwell, D. E. Smith, S. C. Davies, A. McNulty, P. Keen, 
P. Cunningham and R. Guy “Barriers to HIV testing and characteristics associated with 
never testing among gay and bisexual men attending sexual health clinics in Sydney,” 
Journal of the International AIDS Society, pp. 1–8, 2015.
[49] A. Bourne, D. Reid, F. Hickson, S. Torres-Rueda, and P. Weatherburn, “Illicit drug use in 
sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in 
South London: findings from a qualitative study: Table 1,” Sexually Transmitted 
Infections, vol. 91, no. 8, pp. 564–568, 2015.
[50] J. Galbraith, J. H. Willig, J. B. Rodgers, J. P. Donnelly, A. O. Westfall, K. L. Ross-Davis, 
S. L. Heath “Evolution and Escalation of an Emergency Department Routine, Opt-out 
HIV Screening and Linkage-to-Care Program.,” Public Health Reports, vol. 131, pp. 96–
107, 2016.
[51] J. S. Haukoos, E. Hopkins, A. A. Conroy, M. Silverman, R. L. Byyny, S. Eisert, M. W. 
Thrun, M. L. Wilson, A. B. Hutchinson, J. Forsyth, S. C. Johnson, J. D. Heffelfinger, 
“Routine opt-out rapid HIV screening and detection of HIV infection in emergency 
department patients,” JAMA - Journal American Medical Association, vol. 304, no. 1538–
3598 (Electronic), pp. 284–292, 2010.
[52] D. a E. White, T. Sadoun, T. Tran, and H. J. Alter, “Increased acceptance rates of HIV 
screening using opt-out consent methods in an urban emergency department.,” Journal of 
Acquired Immune Deficiency Syndrome, vol. 58, no. 3, pp. 277–82, 2011.
54
Appendix A: Interview Consent Form
 
TITLE: Delayed Diagnosis of HIV in Newfoundland. A Quantitative and Qualitative Study
INVESTIGATOR(S): Sarah Boyd, Peter Daley, Deborah Kelly, Jill Allison, Michael Grant, 
Kim Burt, Carla Penney
You have been invited to take part in a research study.  Taking part in this study is voluntary.  It 
is up to you to decide whether to be in the study or not.  You can decide not to take part in the 
study.  If you decide to take part, you are free to leave at any time.  This will not affect your 
usual health care or normal treatment.
Before you decide, you need to understand what the study is for, what risks you might take and 
what benefits you might receive.  This consent form explains the study.  
Please read this carefully. Take as much time as you like. If you like, take it home to think about 
for a while. Mark anything you do not understand, or want explained better. After you have read it, 
please ask questions about anything that is not clear.
The researchers will:
 discuss the study with you
 answer your questions
 keep confidential any information which could identify you personally
 be available during the study to deal with problems and answer questions
1. Introduction/Background:
The Public Health Agency of Canada says that about 75,500 Canadians are infected with 
HIV but about 21% don’t know they are infected. About 2,570 new HIV infections occurred 
in Canada in 2014.  Because people are still getting infected with HIV more needs to be 
done to make sure people who are at risk get tested. HIV treatment has been shown to help 
people live longer and reduces the rate of infection. We want to know what factors help 
people decide whether or not to get tested so we can provide good health teaching to prevent 
HIV infection.  
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2.    Purpose of study:
The purpose of this study is to try to find out why some people might delay getting tested for 
HIV and what kinds of programs will help people who are at risk get tested earlier in their 
illness.  
3.    Description of the study procedures:
This study uses interviews to find out about how people made the decision to get tested for HIV.  
The researcher has some questions they will ask but you will also be asked if you want to tell us 
anything else about your HIV test and diagnosis.  The researcher will record the interview, if you 
agree, and a member of the research team will type out the answers you give after the interview. 
You can decide not to answer some questions if you chose. 
4.    Length of time:
The interview will last up to 1 hour and will take place at a place where you are comfortable.  
The researcher may contact you to ask a follow up question at some time in the month after the 
interview.  
5.    Possible risks and discomforts:
There are no physical risks to taking part in the study. The researcher will be asking you about 
your HIV diagnosis.  This may be painful or make you feel sad.  If you feel distress during the 
interview, the researcher will end the interview and we will call the social worker at the HIV 
clinic for support. You can stop the interview at any time.
6.    Benefits:
It is not known whether this study will benefit you. 
7.    Liability statement:
Signing this form gives us your consent to be in this study.  It tells us that you understand 
the information about the research study.  When you sign this form, you do not give up your 
legal rights.  Researchers or agencies involved in this research study still have their legal and 
professional responsibilities.
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8.    What about my privacy and confidentiality? 
Protecting your privacy is an important part of this study. Every effort to protect your 
privacy will be made. However it cannot be guaranteed. For example we may be required by 
law to allow access to research records. Your name will not be used and all information that 
might identify you will be taken out before we write about anything you tell us. 
        When you sign this consent form you give us permission to 
 Collect information from you
 Share information with the people conducting the study
 Share information with the people responsible for protecting your safety       
Access to records
The members of the research team will see study records that identify you by name.
Other people may need to look at the study records that identify you by name. This might 
include the research ethics board. You may ask to see the list of these people. They can look 
at your records only when supervised by a member of the research team. 
Use of your study information
The research team will collect and use only the information they need for this research 
study.       
This information will include your 
 information from study interviews 
Your name and contact information will be kept secure by the research team in 
Newfoundland and Labrador.  It will not be shared with others without your permission. 
Your name will not appear in any report or article published as a result of this study.
Information collected for this study will be kept for five years.
If you decide to withdraw from the study, the information collected up to that time will be 
destroyed.  Once the information is used for publication it cannot be removed.  
Information collected and used by the research team will be stored at Memorial University 
Faculty of Medicine.  Dr. Peter Daley is the person responsible for keeping it secure. 
Your access to records
You may ask the study doctor or researcher to see the information that has been collected 
about you.  
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9.    Questions or problems:
If you have any questions about taking part in this study, you can meet with the investigator 
who is in charge of the study.  That person is: Sarah Boyd
Principal Investigator’s Name and Phone Number
Sarah Boyd
709-691-9673
Or you can talk to someone who is not involved with the study at all, but can advise you on 
your rights as a participant in a research study.  This person can be reached through:
                 
Ethics Office at 709-777-6974
      Email at info@hrea.ca
This study has been reviewed and given ethics approval by the Newfoundland and Labrador 
Health Research Ethics Board.
10.   Declaration of financial interest, if applicable  
No persons are receiving money for doing this study.
After signing this consent you will be given a copy.
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Signature Page
Study title: Delayed Diagnosis of HIV in Newfoundland. A Quantitative and Qualitative Study
                                                                                                                                   
Name of principal investigator:    
 Sarah Boyd                                                                                             
To be filled out and signed by the participant:
Please check as appropriate:
I have read the consent . Yes { }     No { }
I have had the opportunity to ask questions/to discuss this study. Yes { }     No { }
I have received satisfactory answers to all of my questions. Yes { }     No { }
I have received enough information about the study. Yes { }     No { }
I have spoken to Sarah Boyd and she has answered my questions Yes { }     No { }
I understand that I am free to withdraw from the study Yes { }     No { }
 at any time
 without having to give a reason
 without affecting my future care 
I understand that it is my choice to be in the study and that I may not benefit. Yes { }     No { }
I understand how my privacy is protected and my records kept confidential    Yes { }     No { }
I agree that the study doctor or investigator may read the parts of my hospital Yes { }     No { }
records which are relevant to the study.
I agree to be audio taped                 Yes { }     No { }
I agree to take part in this study.        Yes { }     No { }
                                                   
___________________________________  _____________________   _______________    
_
Signature of participant Name printed  Year Month Day
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__________________________________ ______________________     ________________
Signature of person authorized as Name printed   Year Month Day
Substitute decision maker, if applicable____________________________________           
__________________________________    ______________________     ________________
To be signed by the investigator or person obtaining consent
I have explained this study to the best of my ability. I invited questions and gave answers. I 
believe that the participant fully understands what is involved in being in the study, any potential 
risks of the study and that he or she has freely chosen to be in the study.
___    _____________________-      
Signature of investigator          Name printed Year Month Day
Telephone number:    _________________________
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Appendix B – HREA Approval
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Appendix C – Chart Review Case Report Form
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Appendix D – Interview Guide
Thank you for agreeing to talk to me about your experience with HIV testing.  Everything you 
tell me will be confidential.  I am also not concerned with how you came to be HIV positive.  
You do not have to share that with me. I am more interested in learning about the way testing is 
accessed and how people make decisions about getting tested. You may choose not to answer 
any of the questions if you’d like.
Can you tell me about yourself?  
How old are you?
How long have you lived in NL?  
Can you tell me about your diagnosis of HIV? 
When were you diagnosed?  
Did you think you might be at risk for HIV?  (again you do not have tell me about your specific 
risk factor if you do not want to) 
Did you know the risk factors for HIV before you got tested?  
How did you decide to get tested for HIV? 
 What lead you to make the decision to be tested? 
a. Did you ask your doctor or did they suggest testing?
If doctor initiated: Was testing offered specifically because your care giver 
identified that you had some risk factors?
Did you ever think about getting tested prior to the time you were diagnosed?  
i. Had you been tested in the past? 
If no: What stopped you from getting tested in the past? 
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Where did you have your HIV test?  
Is testing available in your community?
Can you tell me about the process for getting tested?  
Who gave you the results of your test?
What information were you given by your doctor before the test was done?
What information were you given after you received the results of your test? 
Can you tell me about what has happened since you were tested?  
A. Are you on medication?
b. Have you had some counselling?
c. Who provides care for your HIV 
Is there anything else you want to tell us about the process of getting tested for HIV in your 
community? 
Thank you again for sharing your story with me. If this interview has made you upset in any way 
feel free to contact the social worker Cheryl Schulz. Do you have her number? Her number is 
777-5885.
